|
Regions
|
β1(a)
|
β2(b)
|
β3(c)
|
β4(d)
|
β5(e)
|
β6(f)
|
β7(g)
|
|---|
|
High baseline ACEIs prescription proportion (>74 %)
|
|
North East
|
−0.12 (−0.13, −0.11)
|
---
|
---
|
---
|
0.04 (0.02, 0.06)
|
---
|
---
|
|
South East
|
−0.06 (−0.70, −0.05)
|
−0.31 (−0.7, −0.07)
|
0.02 (0.01, 0.04)
|
---
|
---
|
---
|
---
|
|
Wales
|
---
|
---
|
---
|
---
|
---
|
---
|
---
|
|
East Midlands
|
−0.03 (−0.04, −0.16)
|
---
|
---
|
−0.64 (−1.1, −0.20)
|
0.16 (0.13, 0.19)
|
---
|
---
|
|
Intermediate baseline ACEIs prescription proportion (65 %-74 %)
|
|
Yorkshire and the Humber
|
−0.08 (−0.09, −0.06)
|
---
|
0.20 (0.14, 0.24)
|
−1.80 (−0.26,-0.9)
|
---
|
---
|
---
|
|
East of England
|
−0.08 (−0.70, −0.05)
|
−0.40 (−0.7, −0.05)
|
0.02 (0.04, 0.03)
|
---
|
---
|
---
|
---
|
|
South Central
|
−0.01 (−0.2, −0.002)
|
−0.60 (−0.9, −0.40)
|
---
|
−0.47 (−0.7, −0.20)
|
---
|
---
|
---
|
|
Scotland
|
---
|
---
|
0.06 (0.04, 0.08)
|
−0.49 (−0.80, −0.10)
|
---
|
---
|
---
|
|
West Midlands
|
---
|
---
|
−0.03 (−0.04, −0.02)
|
---
|
---
|
---
|
---
|
|
North West
|
0.01 (0.02, 0.018)
|
−0.57 (−0.8, −0.33)
|
0.04 (0.03, 0.05)
|
---
|
---
|
---
|
---
|
|
London
|
---
|
0.40 (0.20, 0.60)
|
---
|
---
|
0.04 (0.03, 0.05)
|
---
|
---
|
|
Low baseline ACEIs prescription proportion (<65 %)
|
|
South East Coast
|
0.013 (0.004, 0.02)
|
−0.42 (−0.7, −0.20)
|
−0.02 (−0.03,-0.002)
|
---
|
---
|
---
|
---
|
|
Northern Ireland
|
0.06 (0.05, 0.08)
|
---
|
---
|
---
|
0.06 (0.02, 0.09)
|
---
|
---
|
- Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); (a)baseline trend; (b)level change following BCBV policy; (c)trend change following BCBV policy; (d)level change following generic losartan availability; (e)trend change following generic losartan availability; (f)level change following generic perindopril availability; (g)trend change following generic perindopril availability; −--: indicates insignificant estimates at 0.05 level, after stepwise backward elimination; ACEIs: Angiotensin converting enzyme inhibitors
